Hyperuricemia - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Hyperuricemia - Pipeline Review, H2 2018’, provides an overview of the Hyperuricemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hyperuricemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyperuricemia

- The report reviews pipeline therapeutics for Hyperuricemia by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Hyperuricemia therapeutics and enlists all their major and minor projects

- The report assesses Hyperuricemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Hyperuricemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hyperuricemia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hyperuricemia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allena Pharmaceuticals Inc

CymaBay Therapeutics Inc

Fuji Yakuhin Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Nippon Chemiphar Co Ltd

Nobelpharma Co Ltd

Polaris Pharmaceuticals Inc ...

Allena Pharmaceuticals Inc

CymaBay Therapeutics Inc

Fuji Yakuhin Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Nippon Chemiphar Co Ltd

Nobelpharma Co Ltd

Polaris Pharmaceuticals Inc

Teijin Pharma Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hyperuricemia – Overview

Hyperuricemia – Therapeutics Development

Pipeline Overview

Pipeline by Companies ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hyperuricemia – Overview

Hyperuricemia – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hyperuricemia – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hyperuricemia – Companies Involved in Therapeutics Development

Allena Pharmaceuticals Inc

CymaBay Therapeutics Inc

Fuji Yakuhin Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Nippon Chemiphar Co Ltd

Nobelpharma Co Ltd

Polaris Pharmaceuticals Inc

Teijin Pharma Ltd

Hyperuricemia – Drug Profiles

ALLN-346 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

allopurinol – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arhalofenate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CS-3001 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

febuxostat – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FYU-981 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JPH-367 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NC-2500 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NC-2700 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPCX-3 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegadricase – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFR-9350 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-4640 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Xanthine Oxidase for Hyperuricemia – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TEI-A – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TMX-049 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hyperuricemia – Dormant Projects

Hyperuricemia – Discontinued Products

Hyperuricemia – Product Development Milestones

Featured News & Press Releases

Jun 19, 2018: Allena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for Hyperuricemia in the Setting of Advanced Chronic Kidney Disease

Jun 08, 2018: Selecta Biosciences to Present Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018

Nov 29, 2017: Nippon Chemiphar Announces Progress on Its Hyperuricemia/Gout Projects; NC-2500 Shows Favorable Profile to Lower Serum Uric Acid in Phase-1 Study

Apr 21, 2017: Mylan Receives CHMP Positive Opinion For Febuxostat

Dec 07, 2016: Selecta Presents Phase 1 Clinical Data for Lead Product Candidate, SEL-212, in Patients with Hyperuricemia at 11th Annual IMVAC Summit

Jun 15, 2016: Scottish Medicines Consortium Accepts Adenuric (Febuxostat) for the Prevention and Treatment of Hyperuricaemia and Predicts Savings for NHS Scotland

May 23, 2016: Teijin Pharma’s Feburic (Febuxostat) Approved as Indication for Cancer Chemotherapy-Induced Hyperuricemia

Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6 - 11

Jun 30, 2015: New Indication for Teijin Pharma’s Febuxostat in Europe

Jan 12, 2015: Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat

Nov 05, 2013: Teijin Pharma files patent infringement suit against Dr Reddy's

Nov 01, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Uloric

Apr 11, 2012: Teijin Pharma And Menarini Sign Distribution Agreement For Marketing Of Febuxostat

Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat

Jul 28, 2011: Teijin Pharma Launches Febuxostat In Korea

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hyperuricemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Tables

Number of Products under Development for Hyperuricemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Hyperuricemia – Pipeline by Allena Pharmaceuticals Inc, H2 2018

Hyperuricemia – Pipeline by CymaBay Therapeutics Inc, H2 2018

Hyperuricemia – Pipeline by Fuji Yakuhin Co Ltd, H2 2018

Hyperuricemia – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018

Hyperuricemia – Pipeline by Nippon Chemiphar Co Ltd, H2 2018

Hyperuricemia – Pipeline by Nobelpharma Co Ltd, H2 2018

Hyperuricemia – Pipeline by Polaris Pharmaceuticals Inc, H2 2018

Hyperuricemia – Pipeline by Teijin Pharma Ltd, H2 2018

Hyperuricemia – Dormant Projects, H2 2018

Hyperuricemia – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Hyperuricemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Figures

Number of Products under Development for Hyperuricemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports